Karen Soares, Clover Health’s chief legal officer, sold 6,846 shares at $4.78 each on 2026-09-15. The transaction represented about 0.4% of her prior holding, and she owned 1,607,371 shares afterward, giving investors the reported scale of the sale and her remaining position.
Key Highlights
- The transaction occurred on 15 September 2026.
- The filing lists SEC transaction code S.
- Karen Soares owned 1,607,371 shares after the transaction.
CLOVER HEALTH INVESTMENTS, CORP. /DE (NASDAQ: CLOV) Chief Legal Officer Karen Soares sold 6,846 shares at $4.78 per share. The filing reported Soares’ sale of shares in the company.
Transaction Date and Filing Code
The sale took place on 15 September 2026. Its SEC transaction code was S. Karen Soares was identified as CLOVER HEALTH INVESTMENTS, CORP. /DE’s chief legal officer. The reported transaction involved 6,846 shares, with each share priced at $4.78. The filing identifies the transaction with SEC code S. The filing gives the sale date as 15 September 2026 and the reported price as $4.78 per share.
Post-Transaction Ownership
Soares owned 1,607,371 shares after completing the sale. The filing states that the transaction represented about 0.4% of her prior shareholding. The filing reports the sale, the percentage of prior shareholding it represented, and the post-transaction ownership figure.
FAQs
Q: What was Karen Soares’ CLOV insider transaction price?
A: Karen Soares sold 6,846 CLOVER HEALTH INVESTMENTS, CORP. /DE shares at $4.78 per share, according to the Form 4 filing. The sale occurred on 15 September 2026.
Q: How many CLOV shares did Karen Soares own after the sale?
A: Following the transaction, Karen Soares owned 1,607,371 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE. The filing identifies her as the company’s chief legal officer.
Q: What does transaction code S mean for the CLOV sale?
A: Transaction code S denotes an open-market or private sale.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.